Vivakor, Inc. annual report, Q4 FY2009

Vivakor, Inc. 10-K Summary (Fiscal Year Ended Dec 31, 2009)

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2009, for Vivakor, Inc., a transdisciplinary research company based in Coralville, Iowa. The company focuses on molecular medicine, electro-optics, biological handling, and natural compounds. Vivakor operates as a "research hub," developing technologies for commercialization through licensing or direct sales. Key activities in 2009 included the commencement of sales for cryovials and nutraceuticals, the acquisition of HealthAmerica assets (MRI technology) in late 2008, and a strategic license agreement with Regeneca International, Inc. for the distribution of the VivaBoost beverage.

Key Financial Metrics

Metric 2009 2008
Total Revenue $149,417 $194,700
Net Loss $(1,945,259) $(1,031,788)
Net Loss Per Share (Basic/Diluted) $(0.04) $(0.02)
Cash and Cash Equivalents (End of Period) $187,646 $145,669
Accumulated Deficit $(3,420,661) $(1,048,960)
Total Current Liabilities $2,216,301 $2,410,617
Research & Development Expenses $1,138,091 $443,107
Patent Amortization $741,939 $123,656

Liquidity and Debt: The company reported a working capital deficit. Current liabilities included $828,018 in accrued wages, $347,572 in loans/advances from related parties, and a $505,058 note payable related to the HealthAmerica acquisition. The company has not made all required scheduled payments on the HealthAmerica note.

Material Changes vs. Prior Period

  • Revenue Composition: Revenue sources shifted significantly. In 2008, revenue was primarily from research services ($194,700). In 2009, research services revenue dropped to zero, replaced by product sales ($30,435), license fees ($6,070), and a government grant ($112,912).
  • Expense Growth: Net loss nearly doubled, driven by a 157% increase in R&D expenses (largely due to patent amortization) and the write-off of $111,316 in abandoned offering costs from a terminated capital raise.
  • Debt Restructuring: The company reduced a $1.48 million note payable by $1.02 million through the issuance of 4.4 million shares of common stock to a creditor.
  • Equity Transactions: Significant share issuances occurred in 2009 for cash, services, and debt reduction, increasing outstanding shares from ~50.2 million to ~63.0 million.

Guidance, Outlook, Risks, and Unusual Items

Going Concern: The independent auditors have expressed substantial doubt about the company's ability to continue as a going concern due to a lack of working capital and a history of losses. The company states it does not have sufficient cash to fund operations for the next twelve months without additional financing.

Outlook and Strategy: Management plans to raise capital through debt or equity offerings and strategic partnerships. A key milestone is the $5 million purchase commitment from Regeneca for VivaBoost over 36 months, though the first order fulfillment was expected in Q1 2010.

Risks:

  • Financing: Failure to raise additional capital could force the company to curtail operations or cease business.
  • Product Development: Most products are in early development phases (Phase I or II) and require regulatory approval (FDA) before commercial viability.
  • Intellectual Property: Due to lack of funds, 13 provisional patent applications were allowed to expire in the past.
  • Related Party Transactions: Significant revenue and debt are tied to related parties, including Regeneca and stockholders who provided advances.

Unusual Items: The $111,316 write-off of deferred offering costs related to a terminated S-1 registration in early 2009 was a non-recurring expense impacting the bottom line.

Investor Verification Checklist

  • Cash Runway: Verify current cash balances and the status of the $1.1 million in notes receivable from stock purchases (as of March 2010) to assess immediate liquidity.
  • Regeneca Agreement: Confirm if the $5 million purchase commitment from Regeneca has been fulfilled or if the agreement has been modified/terminated due to missed milestones.
  • Debt Compliance: Check the status of the $505,058 HealthAmerica note payable, specifically regarding the missed monthly payments and the 10% gross proceeds payment clause.
  • Product Commercialization: Validate the regulatory status of key products (VivaSight, Cryopsy, SLICES) and whether any have achieved FDA clearance or commercial sales beyond the initial cryovials.
  • Dilution Risk: Review the impact of recent convertible notes issued in early 2010 (Feb/March) which have anti-dilution provisions and low conversion prices (58% of lowest bid).
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.